Vol 55, No 5 (2024)
Clinical vignette
Published online: 2024-10-18
Managing post-transplant relapse in FLT3-mutated AML with gilteritinib
1
, 1, 1
, 1, 1
DOI: 10.5603/ahp.102537
Acta Haematol Pol 2024;55(5):285-286.
Abstract
Not available
Keywords: acute myeloid leukemiaFLT3-ITD mutationgilteritinibhematopoietic stem cell transplantation
References
- Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019; 33(2): 299–312.
- Russell-Smith TA, Gurskyte L, Muresan B, et al. Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature review. Future Oncol. 2022; 18(16): 2029–2039.
- Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. N Engl J Med. 2019; 381(18): 1728–1740.
- Wierzbowska A, Pluta A, Stelmach P, et al. A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) - the Polish Adult Leukemia Group AML-1/2018 Study. Blood. 2023; 142(Supplement 1): 5914–5914.
- Andrews C, Pullarkat V, Recher C. CPX-351 in FLT3-mutated acute myeloid leukemia. Front Oncol. 2023; 13: 1271722.
- Perrone S, Ottone T, Zhdanovskaya N, et al. How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication? Cancer Drug Resist. 2023; 6(2): 223–238.
- Kennedy VE, Smith CC. FLT3 targeting in the modern era: from clonal selection to combination therapies. Int J Hematol. 2023 [Epub ahead of print].
